KLDO (Kaleido Biosciences) ROCE %: -226.75% (As of Dec. 2021)


What is Kaleido Biosciences ROCE %?

Kaleido Biosciences KLDO ROCE % is -226.75% as of Dec. 2021.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kaleido Biosciences's annualized ROCE % for the quarter that ended in Dec. 2021 was -226.75%.

Kaleido Biosciences  (OTCPK:KLDO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kaleido Biosciences ROCE % Related Terms

Kaleido Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences ROCE % Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROCE %
Get a 7-Day Free Trial -176.86 -120.37 -116.96 -137.54 -277.00

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -151.61 -132.50 -112.97 -148.48 -226.75

Kaleido Biosciences ROCE % Calculation

Kaleido Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-87.45/( ( (59.344 - 16.659) + (50.137 - 29.682) )/ 2 )
=-87.45/( (42.685+20.455)/ 2 )
=-87.45/31.57
=-277.00 %

Kaleido Biosciences's ROCE % of for the quarter that ended in Dec. 2021 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=-78.228/( ( (67.804 - 19.261) + (50.137 - 29.682) )/ 2 )
=-78.228/( ( 48.543 + 20.455 )/ 2 )
=-78.228/34.499
=-226.75 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -226.75% mean?
Kaleido Biosciences (KLDO) has a ROCE % of -226.75% as of Dec. 2021.
Is Kaleido Biosciences' ROCE % too high?
Kaleido Biosciences' current ROCE % is -226.75%.
How does Kaleido Biosciences' ROCE % compare to NPTX and GSTC?
Kaleido Biosciences' ROCE % of -226.75% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Kaleido Biosciences's current ROCE % is -226.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current ROCE % of -226.75%. The current ROCE % is -226.75%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current ROCE % is -226.75% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.